Skip to main content

Table 2 Clinical information of KHP PCaBB participants from Jan 2013-Dec 2015

From: King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB)

Clinical Variable Consented
(n = 549)
Treatment type
 Surgery 357 (65.0)
 Active Monitoring 74 (13.5)
 Anti-cancer drug regimen (Hormone Therapy) 98 (17.9)
 Anti-cancer drug regimen (Cytotoxic Chemotherapy) 2 (0.4)
 Brachytherapy 18 (3.3)
 Specialist palliative care 0 (0.0)
Mean PSA (SD) at diagnosis (μg/L) 42.77 (±374.927)
Gleason Score
 6 74 (13.5)
 7 358 (65.2)
 8 44 (8.0)
 9 53 (9.7)
 10 3 (0.5)
 Unrecorded 19 (3.5)
Gleason Group
 Grade 1 74 (13.5)
 Grade 2 247 (45.0)
 Grade 3 111 (20.2)
 Grade 4 44 (8.0)
 Grade 5 56 (10.2)
T stage
 TX 42 (7.7)
 T0 28 (5.1)
 T1 4 (0.7)
 T1a 2 (0.4)
 T1b 0 (0.0)
 T1c 16 (2.9)
 T2 106 (19.3)
 T2a 153 (27.9)
 T2b 15 (2.7)
 T2c 60 (10.9)
 T3 17 (3.1)
 T3a 69 (12.6)
 T3b 34 (6.2)
 T4 3 (0.5)
 T4a 0 (0.0)
N stage
 NX 191 (34.8)
 N0 334 (60.8)
 N1 24 (4.4)
 N2 0 (0.0)
M stage
 MX 221 (40.3)
 M0 315 (57.4)
 M1 5 (0.9)
 M1a 1 (0.2)
 M1b 5 (0.9)
 M1c 2 (0.4)
Risk Category
 Localised prostate cancer  
  Low risk 83 (15.1)
  Intermediate risk 252 (45.9)
  High Risk 157 (28.6)
 Regionally metastatic/ Locally advanced 23 (4.2)
 Distant metastasis 25 (4.6)
 Unrecorded 9 (1.6)
Comorbidities
 Mean number of comorbidities (SD) 1.9 (±2.021)
 Previous/other cancer 20 (3.6)
 Cardiovascular disease 218 (39.7)
 HIV or Infectious Diseases 5 (0.9)
 Hyperlipidaemia and hypercholesterolemia 87 (4.8)
 Diabetes 68 (3.8)
 Psychological 32 (5.8)
Mean number of medications (SD) 2.213 (±2.529)
Erectile dysfunction medication 216 (39.3)
Outcome
 Disease stable 444 (80.9)
 Discharged to GP 56 (10.2)
 Treatment discharged to GP 17 (3.1)
 Discharged to different hospital 4 (0.7)
 Progression 7 (1.3)
 Progression to metastasis 3 (0.5)
 Recurrence 2 (0.4)
 Death 6 (1.1)
 Awaiting treatment 2 (0.4)
 Refused further treatment 1 (0.2)
 Treated privately 1 (0.2)
 Lost to follow up 6 (1.1)
Involvement in clinical trial 34 (6.2)